



- (51) **International Patent Classification:**
C07K 16/30 (2006.01) *A61K 39/00* (2006.01)
- (21) **International Application Number:**
PCT/US2021/022627
- (22) **International Filing Date:**
16 March 2021 (16.03.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/990,927 17 March 2020 (17.03.2020) US
63/037,374 10 June 2020 (10.06.2020) US
63/074,956 04 September 2020 (04.09.2020) US
- (71) **Applicant:** PTM THERAPEUTICS, INC. [US/US]; 7 Forty-First Ave, #318, San Mateo, California 94403 (US).
- (72) **Inventors:** PRESTA, Leonard; c/o PTM Therapeutics, Inc., 7 Forty-First Ave, #318, San Mateo, California 94403 (US). LIANG, Tony; c/o PTM Therapeutics, Inc., 7 Forty-First Ave, #318, San Mateo, California 94403 (US). CHENG, Jennifer; c/o PTM Therapeutics, Inc., 7 Forty-First Ave, #318, San Mateo, California 94403 (US).
- (74) **Agent:** MEZA GUTIERREZ, Fernando et al.; Morrison & Foerster LLP, 425 Market Street, San Francisco, California 94105-2482 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) **Title:** ANTI-GLYCAN ANTIBODIES AND USES THEREOF




FIG. 2C

(57) **Abstract:** The present disclosure provides antibodies, or an antigen binding portion thereof, that bind to sLeA and sLeC, as well as polynucleotides, vectors, host cells, pharmaceutical compositions, and methods related thereto.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*